美國植物來源原料藥（API）市場規模、佔有率和趨勢分析報告：按分子類型、最終用途和細分市場預測（2025-2033 年）

美國植物來源原料藥市場概述

2024年美國植物來源原料藥（API）市場規模估計為96.9億美元，預計2033年將達到157.7億美元。

預計2025年至2033年間，該市場將以5.5%的複合年成長率成長。天然且永續的藥物成分日益普及，推動了市場強勁成長。消費者對草藥和植物來源治療方法的偏好不斷增強，也帶動了對合成添加劑更少、安全性更高的藥物的需求。

製藥公司正集中研發力量，致力於發現新的生物活性化合物並開發療效較佳的製劑。萃取、純化和分析技術的進步提高了植物來源原料藥的產量、均一性和穩定性，從而生產出符合嚴格標準的高品質產品。例如，2025年9月，《分子生物學最新進展》（Current Issues in Molecular Biology）報告稱，代謝工程已將Terpenoids（包括紫杉醇）的產量提高了25倍，青蒿素的產量提高了38%。多組體學方法和CRISPR技術解決了天然產物產量低和規模化生產難題，為從實驗室規模生產向工業化生產過渡鋪平了道路。這些創新正在推動植物來源藥物成分（API）廣泛應用於主流藥物，拓展治療選擇，並增強消費者信心。

技術進步是市場擴張的關鍵驅動力。植物組織培養、酵素輔助萃取和生物修復等技術能夠在維持療效的同時，實現高品質原料藥的規模化生產。包括層析法和光譜的先進分析技術，能夠確保生物活性化合物的準確鑑定和定量，並降低生產過程中的變異性。這些改進提升了產品質量，最佳化了生產成本，並支持了大規模商業化。整合生物技術和傳統植物萃取技術的生產平台能夠實現高效穩定的生產。這些進步正在吸引新的市場參與企業，並鼓勵現有公司拓展其植物來源產品系列。技術和製程的持續創新提升了植物來源原料藥的潛力，從而能夠發現用於多種治療應用的新型化合物。

美國慢性病和文明病的日益普遍，進一步推動了對植物來源藥物成分（API）的需求。植物植物來源化合物正擴大被用於治療心血管疾病、糖尿病、發炎和神經退化性疾病等。製藥公司與研究機構之間的合作正在加速新分子的發現，並支持有效治療方法的開發。例如，2025年3月，學術期刊《天然產物與生物探勘》（Natural Products and Bioprospecting）報告了從曲霉屬真菌中分離出217種新型Terpenoids，顯示真菌是抗菌化合物的未開發來源。人們對補充和整合醫學日益成長的興趣也為市場擴張提供了更多機會。儘管正在進行的臨床研究已證實了其療效和安全性，但製造商正利用這些發現來開發創新劑型，這將推動美國植物來源原料藥市場在未來十年內保持強勁且持續的成長。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章美國植物來源原料藥市場變數、趨勢與範圍

• 市場譜系展望
• 市場動態
• 商業環境分析
  • 產業分析—波特五力分析
  • PESTLE分析
  • 管道分析
  • 專利到期分析
  • 定價分析

第4章美國植物來源原料藥市場：依分子類型分類的商業分析

• 按分子類型分類的市場佔有率（2024 年和 2033 年）
• 按分子類型分類的市場規模、預測和趨勢分析（2021-2033 年）
• 生物鹼
• 花青素
• 黃酮類化合物
• 酚酸
• Terpenoids
• 木質素和芪
• 其他

第5章美國植物來源原料藥市場：依最終用途分類的業務分析

• 按最終用途分類的市場佔有率（2024 年和 2033 年）
• 市場規模、預測與趨勢分析（按應用領域分類，2021-2033 年）
• 製藥
• 營養補充品
• 草藥產業
• 其他

第6章 競爭情勢

• 參與公司概況
• 企業市場分析
• 公司分類
• 策略規劃
• 公司簡介/列表
  • Brains Bioceutical Corp.
  • Arboris LLC
  • Cargill, Incorporated
  • Roquette
  • HimPharm
  • Kothari Phytochemicals &Industries Ltd.
  • BASF
  • Evonik Industries
  • Alchem International
  • Sami-Sabinsa Group

U.S. Plant-based API Market Summary

The U.S. plant-based API market size was estimated at USD 9.69 billion in 2024 and is projected to reach USD 15.77 billion by 2033, growing at a CAGR of 5.5% from 2025 to 2033. The market is witnessing strong growth due to the increasing adoption of natural and sustainable pharmaceutical ingredients. Rising consumer preference for herbal and plant-derived therapies drives demand for medications with fewer synthetic additives and improved safety profiles.

Pharmaceutical companies are focusing on research to identify new bioactive compounds and develop formulations with enhanced efficacy. Advances in extraction, purification, and analytical technologies have improved the yield, consistency, and stability of plant-based APIs, yielding high-quality products that meet stringent standards. For instance, in September 2025, Current Issues in Molecular Biology reported that metabolic engineering raised terpenoid production, including paclitaxel, by 25 fold and enhanced artemisinin yield by 38%. Multi-omics approaches and CRISPR tools addressed low natural yields and scale-up challenges, providing a roadmap for translating lab-scale production into industrial manufacturing. These innovations support broader integration of plant-based APIs in mainstream pharmaceuticals, expanding therapeutic options and strengthening consumer confidence.

Technological advancements are a major factor in market expansion. Methods such as plant tissue culture, enzyme-assisted extraction, and biorementation enable the scalable production of high-quality APIs while maintaining therapeutic effectiveness. Sophisticated analytical techniques, including chromatography and spectroscopy, ensure precise identification and quantification of bioactive compounds, reducing variability in manufacturing. These improvements enhance product quality and optimize production costs, supporting large-scale commercialization. Integrated production platforms combining biotechnology with traditional plant extraction enable efficient and consistent manufacturing. Such progress attracts new players to the market and encourages established companies to expand their plant-based product portfolios. Continuous innovation in technology and processing enhances the potential of plant-based APIs, enabling the discovery of novel compounds for diverse therapeutic applications.

Rising prevalence of chronic and lifestyle-related diseases in the U.S. further fuels demand for plant-based APIs. Conditions such as cardiovascular disorders, diabetes, inflammation, and neurodegenerative diseases are increasingly addressed using plant-derived compounds due to their targeted therapeutic benefits. Collaborations between pharmaceutical firms and research institutions accelerate the discovery of novel molecules and support the development of effective treatments. For instance, in March 2025, Natural Products and Bioprospecting reported the isolation of 217 new terpenoids from Aspergillus species, highlighting fungi as an under-exploited source of antimicrobial compounds. The growing interest in complementary and integrative medicine presents additional opportunities for market expansion. Continuous clinical studies validate efficacy and safety, while manufacturers leverage these insights to develop innovative dosage forms, ensuring strong and sustained growth for the U.S. plant-based API market over the coming decade.

U.S. Plant-based API Market Report Segmentation

This report forecasts revenue growth at the country level and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the U.S. plant-based API market report based on molecule type and end use:

• Molecule Type Outlook (Revenue, USD Million, 2021 - 2033)
• Alkaloids
• Anthocyanin
• Flavonoids
• Phenolic Acids
• Terpenoids
• Lignin and Stilbenes
• Others
• End Use Outlook (Revenue, USD Million, 2021 - 2033)
• Pharmaceuticals
• Nutraceuticals
• Herbal Based Industries
• Others

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Molecule Type
  • 1.2.2. End Use
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. U.S. Plant-based API Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. U.S. Plant-based API Market: Molecule Type Business Analysis

• 4.1. Molecule Type Market Share, 2024 & 2033
• 4.2. Molecule Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Molecule Type, 2021 to 2033 (USD Million)
• 4.4. Alkaloids
  • 4.4.1. Alkaloids Market, 2021 - 2033 (USD Million)
• 4.5. Anthocyanin
  • 4.5.1. Anthocyanin Market, 2021 - 2033 (USD Million)
• 4.6. Flavonoids
  • 4.6.1. Flavonoids Market, 2021 - 2033 (USD Million)
• 4.7. Phenolic Acids
  • 4.7.1. Phenolic Acids Market, 2021 - 2033 (USD Million)
• 4.8. Terpenoids
  • 4.8.1. Terpenoids Market, 2021 - 2033 (USD Million)
• 4.9. Lignin and Stilbenes
  • 4.9.1. Lignin and Stilbenes Market, 2021 - 2033 (USD Million)
• 4.10. Others
  • 4.10.1. Others Market, 2021 - 2033 (USD Million)

Chapter 5. U.S. Plant-based API Market: End Use Business Analysis

• 5.1. End Use Market Share, 2024 & 2033
• 5.2. End Use Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by end use, 2021 to 2033 (USD Million)
• 5.4. Pharmaceuticals
  • 5.4.1. Pharmaceuticals Market, 2021 - 2033 (USD Million)
• 5.5. Nutraceuticals
  • 5.5.1. Nutraceuticals Market, 2021 - 2033 (USD Million)
• 5.6. Herbal Based Industries
  • 5.6.1. Herbal Based Industries Market, 2021 - 2033 (USD Million)
• 5.7. Others
  • 5.7.1. Others Market, 2021 - 2033 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Participant Overview
• 6.2. Company Market Position Analysis
• 6.3. Company Categorization
• 6.4. Strategy Mapping
• 6.5. Company Profiles/Listing
  • 6.5.1. Brains Bioceutical Corp.
    • 6.5.1.1. Overview
    • 6.5.1.2. Financial Performance
    • 6.5.1.3. Product Benchmarking
    • 6.5.1.4. Strategic Initiatives
  • 6.5.2. Arboris LLC
    • 6.5.2.1. Overview
    • 6.5.2.2. Financial Performance
    • 6.5.2.3. Product Benchmarking
    • 6.5.2.4. Strategic Initiatives
  • 6.5.3. Cargill, Incorporated
    • 6.5.3.1. Overview
    • 6.5.3.2. Financial Performance
    • 6.5.3.3. Product Benchmarking
    • 6.5.3.4. Strategic Initiatives
  • 6.5.4. Roquette
    • 6.5.4.1. Overview
    • 6.5.4.2. Financial Performance
    • 6.5.4.3. Product Benchmarking
    • 6.5.4.4. Strategic Initiatives
  • 6.5.5. HimPharm
    • 6.5.5.1. Overview
    • 6.5.5.2. Financial Performance
    • 6.5.5.3. Product Benchmarking
    • 6.5.5.4. Strategic Initiatives
  • 6.5.6. Kothari Phytochemicals & Industries Ltd.
    • 6.5.6.1. Overview
    • 6.5.6.2. Financial Performance
    • 6.5.6.3. Product Benchmarking
    • 6.5.6.4. Strategic Initiatives
  • 6.5.7. BASF
    • 6.5.7.1. Overview
    • 6.5.7.2. Financial Performance
    • 6.5.7.3. Product Benchmarking
    • 6.5.7.4. Strategic Initiatives
  • 6.5.8. Evonik Industries
    • 6.5.8.1. Overview
    • 6.5.8.2. Financial Performance
    • 6.5.8.3. Product Benchmarking
    • 6.5.8.4. Strategic Initiatives
  • 6.5.9. Alchem International
    • 6.5.9.1. Overview
    • 6.5.9.2. Financial Performance
    • 6.5.9.3. Product Benchmarking
    • 6.5.9.4. Strategic Initiatives
  • 6.5.10. Sami-Sabinsa Group
    • 6.5.10.1. Overview
    • 6.5.10.2. Financial Performance
    • 6.5.10.3. Product Benchmarking
    • 6.5.10.4. Strategic Initiatives

List of Tables

• Table 1 List of secondary sources
• Table 2 List of abbreviations
• Table 3 US plant-based API market, by molecule type, 2021 - 2033 (USD Million)
• Table 4 US plant-based API market, by end use, 2021 - 2033 (USD Million)

List of Figures

• Fig. 1 U.S. Plant-based API market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value-chain-based sizing & forecasting
• Fig. 7 Market formulation & validation
• Fig. 8 Market snapshot
• Fig. 9 Competitive landscape
• Fig. 10 U.S. Plant-based API market dynamics
• Fig. 11 U.S. Plant-based API market: Porter's five forces analysis
• Fig. 12 U.S. Plant-based API market: PESTLE analysis
• Fig. 13 Molecule Type market, 2021 - 2033 (USD Million)
• Fig. 14 Alkaloids market, 2021 - 2033 (USD Million)
• Fig. 15 Anthocyanin market, 2021 - 2033 (USD Million)
• Fig. 16 Flavonoids market, 2021 - 2033 (USD Million)
• Fig. 17 Phenolic Acids market, 2021 - 2033 (USD Million)
• Fig. 18 Terpenoids market, 2021 - 2033 (USD Million)
• Fig. 19 Lignin and Stilbenes market, 2021 - 2033 (USD Million)
• Fig. 20 Others market, 2021 - 2033 (USD Million)
• Fig. 21 End use market, 2021 - 2033 (USD Million)
• Fig. 22 Pharmaceuticals market, 2021 - 2033 (USD Million)
• Fig. 23 Nutraceuticals market, 2021 - 2033 (USD Million)
• Fig. 24 Herbal Based Industries market, 2021 - 2033 (USD Million)
• Fig. 25 Others market, 2021 - 2033 (USD Million)
• Fig. 26 Company categorization
• Fig. 27 Company market position analysis
• Fig. 28 Strategic framework